Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2006

View Archived Issues

Speedel retains rights to SPP-200

MorphoSys signs second PER.C6 license agreement

TolerRx raises funding to develop TRX-4

Alantos begins phase I study with ALS 2-0426

Polyfunctional CD8+ HIV-1-specific T-cell responses seen with Remune

TNX-355 activity described in vitro and in clinical trial

GS-9137/ritonavir can be administered with zidovudine and emtricitabine/tenofovir

BTA-798 begins phase Ib study

Novel agents for treating neurological disorders disclosed in recent patent literature

Preclinical findings support the application of talnetant for schizophrenia

Novel treatment options for metabolic disorders described in recent Merck and Dainippon patents

Novel antiinfective agents disclosed in recent patent literature

TAMs get attention as drug targets

Epix and Predix complete merger

Geron report on the anti-HIV activity of their telomerase activator TAT-0002

Sirion Therapeutics completes merger with Sytera

Antisoma updates AS-1404 development progress

Novel agents for thrombotic disorders disclosed in recent Astellas patent

Further findings for Viprovex in anthrax testing

Cesamet now available for CINV

MaxCyte and Medinet collaborate on immuno-cell therapy

Marqibo studied in phase II trial for relapsed and refractory ALL

Enrollment completed in European phase III trial for LidoPAIN SP

Tindamax submitted for bacterial vaginosis

NeuroSearch cleared to begin phase IIb obesity study of tesofensine

Approvable letter for Arxxant

MedImmune files IND for MT-103

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...